Literature DB >> 25093216

Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma Queensland, Australia, 1982-2010.

Danny R Youlden, Philippa H Youl, H Peter Soyer, Joanne F Aitken, Peter D Baade.   

Abstract

IMPORTANCE: Melanoma survivors are known to have a highly elevated risk of subsequent primary melanomas.
OBJECTIVE: To determine the relative risk of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma, with a focus on body site. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was conducted using population-based administrative data for melanoma diagnoses collected by the Queensland Cancer Registry, Queensland, Australia. Deidentified records of all cases of melanoma among Queensland residents during the period 1982-2005 were obtained and reviewed to December 31, 2010. There were 39,668 eligible cases of first primary invasive melanoma and 22,845 cases of first primary in situ melanoma. MAIN OUTCOMES AND MEASURES: Standardized incidence ratios (SIRs), a proxy measure for relative risk, were calculated by dividing the observed number of subsequent primary invasive melanomas by the product of the strata-specific incidence rates that occurred in the general population and the cumulative time at risk for the cohort. Synchronous subsequent melanomas (diagnosed within 60 days of the first primary melanoma) were excluded. Differences between SIRs were assessed using multivariate negative binomial regression adjusted for sex, age group, time to second diagnosis, and body site and expressed in terms of adjusted SIR ratios with corresponding 95% CIs.
RESULTS: There were 5358 subsequent primary invasive melanomas diagnosed, resulting in SIRs of 5.42 (95% CI, 5.23-5.61) and 4.59 (4.37-4.82) for persons with a first primary invasive or in situ melanoma, respectively. The SIRs remained elevated throughout the follow-up period. In general, subsequent primary invasive melanomas were more likely to occur at the same body site as the initial invasive or in situ melanoma. The largest relative risk was for females with a first primary invasive melanoma on the head followed by a subsequent primary invasive melanoma also on the head (SIR, 13.32; 95% CI, 10.28-16.98). CONCLUSIONS AND RELEVANCE: Melanoma survivors require ongoing surveillance, with particular attention required for the body site of the initial lesion. Clinical practice guidelines have recognized the importance of monitoring for people with invasive melanoma; the results of the present study highlight the need for similar levels of supervision for those with a diagnosis of in situ melanoma.

Entities:  

Mesh:

Year:  2014        PMID: 25093216     DOI: 10.1001/jamadermatol.2013.9852

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  9 in total

1.  Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up.

Authors:  Maris S Jones; Hitoe Torisu-Itakura; Devin C Flaherty; Hans F Schoellhammer; Jihey Lee; Myung-Shim Sim; Mark B Faries
Journal:  Am Surg       Date:  2016-10       Impact factor: 0.688

2.  Multiple Primary Melanomas: Retrospective Review in a Tertiary Care Hospital.

Authors:  Rodolfo David Palacios-Diaz; Blanca de Unamuno-Bustos; Carlos Abril-Pérez; Mónica Pozuelo-Ruiz; Javier Sánchez-Arraez; Ignacio Torres-Navarro; Rafael Botella-Estrada
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.964

3.  "Melanoma: Questions and Answers." Development and evaluation of a psycho-educational resource for people with a history of melanoma.

Authors:  Nadine A Kasparian; Shab Mireskandari; Phyllis N Butow; Mbathio Dieng; Anne E Cust; Bettina Meiser; Kristine Barlow-Stewart; Scott Menzies; Graham J Mann
Journal:  Support Care Cancer       Date:  2016-07-27       Impact factor: 3.603

4.  A risk prediction model for the development of subsequent primary melanoma in a population-based cohort.

Authors:  A E Cust; C Badcock; J Smith; N E Thomas; L E Haydu; B K Armstrong; M H Law; J F Thompson; P A Kanetsky; C B Begg; Y Shi; A Kricker; I Orlow; A Sharma; S Yoo; S F Leong; M Berwick; D W Ollila; S Lo
Journal:  Br J Dermatol       Date:  2019-11-27       Impact factor: 9.302

5.  Health Behaviour Changes of Cutaneous Melanoma Survivors in Slovenia - A Qualitative Study.

Authors:  Mirjam Rogl Butina; Igor Švab; Barbara Perić; Igor Bartenjev
Journal:  Zdr Varst       Date:  2019-03-26

6.  Achieving Self-Directed Integrated Cancer Aftercare (ASICA) in melanoma: protocol for a randomised patient-focused pilot trial of delivering the ASICA intervention as a means to earlier detection of recurrent and second primary melanoma.

Authors:  P Murchie; J Masthoff; F M Walter; K Rahman; J L Allan; N Burrows; C Proby; A J Lee; M Johnston; A Durrani; I Depasquale; B Brant; A Neilson; F Meredith; S Treweek; S Hall; A McDonald
Journal:  Trials       Date:  2019-06-03       Impact factor: 2.279

7.  Implementation of patient-reported outcome measures and patient-reported experience measures in melanoma clinical quality registries: a systematic review.

Authors:  Zachary Blood; Anh Tran; Lauren Caleo; Robyn Saw; Mbathio Dieng; Mark Shackleton; H Peter Soyer; Chris Arnold; Graham J Mann; Rachael L Morton
Journal:  BMJ Open       Date:  2021-02-11       Impact factor: 2.692

8.  Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma.

Authors:  Thomas E Pennington; Cathy Yunjia Zhao; Andrew J Colebatch; Pablo Fernandez-Peñas; Pascale Guitera; Hazel Burke; Richard A Scolyer; Alexander M Menzies; Matteo S Carlino; Serigne Lo; Georgina V Long; Robyn Pm Saw
Journal:  Australas J Dermatol       Date:  2022-02-21       Impact factor: 2.481

9.  The Achieving Self-directed Integrated Cancer Aftercare Intervention for Detection of Recurrent and Second Primary Melanoma in Survivors of Melanoma: Pilot Randomized Controlled Trial.

Authors:  Peter Murchie; Lynda Constable; Susan Hall; William Brant; Julia Allan; Marie Johnston; Judith Masthoff; Amanda Lee; Shaun Treweek; Dolapo Ayansina; Charlotte Proby; Kaz Rahman; Fiona Walter; Nigel Burrows; Amer Durrani; Graeme Maclennan
Journal:  JMIR Cancer       Date:  2022-09-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.